[
  {
    "ts": "2026-01-09T00:51:31+00:00",
    "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
    "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
    "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "c02e1d7d-86f0-3c3d-833e-0f605758d4c5",
      "content": {
        "id": "c02e1d7d-86f0-3c3d-833e-0f605758d4c5",
        "contentType": "STORY",
        "title": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
        "description": "",
        "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
        "pubDate": "2026-01-09T00:51:31Z",
        "displayTime": "2026-01-09T00:51:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca",
          "originalWidth": 4950,
          "originalHeight": 3144,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbgNX1ePcKwZLzZG16B47w--~B/aD0zMTQ0O3c9NDk1MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca.cf.webp",
              "width": 4950,
              "height": 3144,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RfLWNvSS9QOylx4dVziNeQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T00:16:35+00:00",
    "headline": "How Pfizer’s AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story",
    "summary": "In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs. Together, these alliances highlight Pfizer’s push to use advanced AI and precision oncology tools to improve its internal pipeline productivity at a time...",
    "url": "https://finance.yahoo.com/news/pfizer-ai-precision-oncology-deals-001635744.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "72cb3f01-a83f-3811-9f78-f73bc0636db0",
      "content": {
        "id": "72cb3f01-a83f-3811-9f78-f73bc0636db0",
        "contentType": "STORY",
        "title": "How Pfizer’s AI and Precision Oncology Deals At Pfizer (PFE) Have Changed Its Investment Story",
        "description": "",
        "summary": "In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs. Together, these alliances highlight Pfizer’s push to use advanced AI and precision oncology tools to improve its internal pipeline productivity at a time...",
        "pubDate": "2026-01-09T00:16:35Z",
        "displayTime": "2026-01-09T00:16:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ai-precision-oncology-deals-001635744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ai-precision-oncology-deals-001635744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:23:30+00:00",
    "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
    "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
    "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-mfn-drug-pricing-deal-branded-medicines/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "ff0d069b-ad61-3460-9dea-e4701a72a4c0",
      "content": {
        "id": "ff0d069b-ad61-3460-9dea-e4701a72a4c0",
        "contentType": "STORY",
        "title": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
        "description": "",
        "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
        "pubDate": "2026-01-09T12:23:30Z",
        "displayTime": "2026-01-09T12:23:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc",
          "originalWidth": 1024,
          "originalHeight": 700,
          "caption": "Johnson & Johnson has inked a drug pricing deal with the White House",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VzpCekl2eIipOcsoKH7yMQ--~B/aD03MDA7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc.cf.webp",
              "width": 1024,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wtqFOx9uBfrdnx.jAIRW4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-mfn-drug-pricing-deal-branded-medicines/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-cuts-mfn-deal-122330905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T13:00:00+00:00",
    "headline": "Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor",
    "summary": "Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa",
    "url": "https://finance.yahoo.com/news/madrigal-expands-mash-pipeline-exclusive-130000029.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b44e4244-49a2-35ba-bfaa-a7865970726c",
      "content": {
        "id": "b44e4244-49a2-35ba-bfaa-a7865970726c",
        "contentType": "STORY",
        "title": "Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor",
        "description": "",
        "summary": "Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa",
        "pubDate": "2026-01-09T13:00:00Z",
        "displayTime": "2026-01-09T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0f914cbbb3adbcda99c74907b0d667e1",
          "originalWidth": 1900,
          "originalHeight": 542,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q0s.L6ObeckTcLeS69OQ3w--~B/aD01NDI7dz0xOTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0f914cbbb3adbcda99c74907b0d667e1.cf.webp",
              "width": 1900,
              "height": 542,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/90TG9W0vr6mFBLDb6YrHoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0f914cbbb3adbcda99c74907b0d667e1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-expands-mash-pipeline-exclusive-130000029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-expands-mash-pipeline-exclusive-130000029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T14:50:00+00:00",
    "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
    "summary": "It could be another tough year for the once-soaring drugmaker.",
    "url": "https://www.fool.com/investing/2026/01/09/prediction-2-healthcare-stocks-that-will-be-worth/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "fb1dc6f6-fe3c-30c3-b797-761ee9fc296d",
      "content": {
        "id": "fb1dc6f6-fe3c-30c3-b797-761ee9fc296d",
        "contentType": "STORY",
        "title": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
        "description": "",
        "summary": "It could be another tough year for the once-soaring drugmaker.",
        "pubDate": "2026-01-09T14:50:00Z",
        "displayTime": "2026-01-09T14:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician and patient discussing the patient's healthcare plan.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xoU0cGmPqAAerl5W7BPCxw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MrOCsdynpkM3tB7i_.kPhA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/09/prediction-2-healthcare-stocks-that-will-be-worth/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-2-healthcare-stocks-worth-145000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T14:16:00+00:00",
    "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
    "url": "https://finance.yahoo.com/news/bmy-rallies-17-3-six-141600419.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "70b11cb9-6dbe-3e78-8bbb-4df9e02e7fdd",
      "content": {
        "id": "70b11cb9-6dbe-3e78-8bbb-4df9e02e7fdd",
        "contentType": "STORY",
        "title": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
        "pubDate": "2026-01-09T14:16:00Z",
        "displayTime": "2026-01-09T14:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-rallies-17-3-six-141600419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-rallies-17-3-six-141600419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T16:19:02+00:00",
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "03266a6e-1b9f-3ef6-8e9d-12bbed252141",
      "content": {
        "id": "03266a6e-1b9f-3ef6-8e9d-12bbed252141",
        "contentType": "STORY",
        "title": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
        "description": "",
        "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
        "pubDate": "2026-01-09T16:19:02Z",
        "displayTime": "2026-01-09T16:19:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786",
          "originalWidth": 800,
          "originalHeight": 475,
          "caption": "FILE PHOTO: Safeway pharmacist Ronak Amin is shown at is work station at the store in Wheaton, Maryland February 13, 2015.    REUTERS/Gary Cameron   (UNITED STATES)/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ESs_JVgpUQvUr8Q6yFeQ3Q--~B/aD00NzU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786.cf.webp",
              "width": 800,
              "height": 475,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GQSAeWySZoA3xd2AMPsRVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T15:51:00+00:00",
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d39c6485-53a9-3f97-8b62-0c5a45561ba8",
      "content": {
        "id": "d39c6485-53a9-3f97-8b62-0c5a45561ba8",
        "contentType": "STORY",
        "title": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
        "description": "",
        "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
        "pubDate": "2026-01-09T15:51:00Z",
        "displayTime": "2026-01-09T15:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tugIemz.T.iquqxVIoxpHw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SHyaOdZAc4DXCya2O4.DtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MKGAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]